Stay Informed on Key Developments

Investor News and Updates

Bill_Ipad

Stay informed about key developments at our company as they happen. Discover our Ad-Hoc Releases and subscribe to our newsletter to receive the latest news and topics of interest.

361 - 370of 392 News
361 - 370of 392 News
December 13, 2017
Not intended for U.S. and UK Media
Bayer receives approval in China for Stivarga® (regorafenib) for the second-line systemic treatment of liver cancer
READ MORE
December 11, 2017
Not intended for U.S. and UK Media
Bayer’s rivaroxaban submitted to U.S. FDA for approval in patients with coronary and/or peripheral artery disease
READ MORE
December 04, 2017
Not intended for U.S. and UK Media - American Association for Cancer Research (AACR) Special Conference on Pediatric Cancer Research:
Updated larotrectinib pediatric clinical trial data demonstrate continued durability of response in TRK fusion cancers
READ MORE
December 01, 2017
CFIUS completes review of proposed merger of Bayer and Monsanto
READ MORE
November 30, 2017
Not intended for U.S. and UK Media
Phase III trial of radium-223 dichloride in combination with abiraterone acetate and prednisone/prednisolone for patients with metastatic castration-resistant prostate cancer unblinded early
READ MORE
November 24, 2017
Not intended for U.S. and UK Media
Phase III study with Amikacin Inhale in addition to standard of care in intubated and mechanically ventilated patients with Gram-negative pneumonia does not meet primary endpoint of superiority
READ MORE
November 15, 2017
Heiko Schipper to join Bayer Board of Management and head Consumer Health Division
READ MORE
November 14, 2017
Not intended for U.S. and UK Media
Bayer and Loxo Oncology to develop and commercialize two novel oncology therapies selectively targeting genetic drivers of cancer
READ MORE
November 06, 2017
Not intended for U.S. and UK Media
Bayer submits application for marketing approval of rivaroxaban for patients with coronary or peripheral artery disease to European Medicines Agency
READ MORE
October 30, 2017
Not intended for U.S. and UK Media
Bayer receives FDA approval for Xarelto® 10 mg once daily for the extended treatment of venous thromboembolism
READ MORE
361 - 370of 392 News
361 - 370of 392 News
Inform Yourself on Special Topics
Control Weeds Not Farming

Control Weeds, Not Farming

LEARN MORE
Farmers discussing their weed management

Everything You Need to Know About Glyphosate

LEARN MORE
some-bayer-group-headquarters

Managing Glyphosate Litigation

learn more
woman harvesting carrots

Managing and Mitigating PCB Litigation Risk

learn more